Thomas McCourt

Tom McCourt joined Ironwood in 2009 and is responsible for the Therapeutic Franchises, Commercial, Drug Development, External Innovation and the GI Insight Center. Tom joined Ironwood as chief commercial officer and senior vice president of marketing and sales. Since then, Tom has designed and implemented Ironwood’s commercial strategy, leading the creation of a sales force and bringing our first medicine, Linzess® (linaclotide) to patients. Prior to joining Ironwood, Tom led the U.S. brand team for denosumab at Amgen Inc. Prior to that, he held a number of senior commercial roles with Novartis AG, including vice president of strategic marketing and operations, where he directed the launch and growth of Zelnorm® (tegaserod maleate) for the treatment of patients with IBS‐C and chronic constipation. He was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec® (omeprazole) and Nexium® (esomeprazole). Tom serves on the board of directors of Acceleron Pharma Inc., as well as the Board of Visitors of the University of Wisconsin – School of Pharmacy where he graduated with a degree in pharmacy.

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.